Cited 0 times in Scipus Cited Count

Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia

DC Field Value Language
dc.contributor.authorSuh, CH-
dc.contributor.authorLee, Y-
dc.contributor.authorYoo, SB-
dc.contributor.authorQuasny, H-
dc.contributor.authorNavarro Rojas, AA-
dc.contributor.authorHammer, A-
dc.contributor.authorSong, YW-
dc.contributor.authorKang, YM-
dc.contributor.authorCho, CS-
dc.contributor.authorPark, W-
dc.contributor.authorKwok, SK-
dc.contributor.authorLee, SG-
dc.contributor.authorChung, WT-
dc.contributor.authorBae, SC-
dc.date.accessioned2024-04-04T06:27:29Z-
dc.date.available2024-04-04T06:27:29Z-
dc.date.issued2024-
dc.identifier.issn1756-1841-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/32445-
dc.description.abstractAim: This post hoc analysis evaluated the efficacy and safety of intravenous belimumab 10 mg/kg in the South Korean subgroup of patients with systemic lupus erythematosus (SLE) enrolled in the North East Asia (NEA) study (GSK Study BEL113750; NCT01345253). Methods: NEA was a double-blind, placebo-controlled, randomized Phase 3 trial. Patients with active, autoantibody-positive SLE were randomized 2:1 to belimumab or placebo plus standard therapy administered on Days 0, 14, and 28, and then every 28 days up to Week 48. The primary efficacy endpoint in this analysis was SLE Responder Index 4 (SRI-4) response rate at Week 52, defined as the proportion of patients achieving a ≥4-point reduction in Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) score, no worsening (<0.3 increase from baseline) in Physician Global Assessment, no new British Isles Lupus Assessment Group (BILAG) A domain and <2 new BILAG B domain scores. Results: Among 100 South Korean patients enrolled in NEA, 54/66 (81.8%) belimumab- and 24/34 (70.6%) placebo-treated patients completed the double-blind phase. Significantly more belimumab- than placebo-treated patients achieved SRI-4 response at Week 52 (n = 35/66, 53.0% vs. n = 8/34, 23.5%; odds ratio [OR; 95% confidence interval (CI)]: 3.67 [1.45, 9.28]; p =.0061). The proportion of patients experiencing ≥1 adverse event was similar between groups (belimumab: n = 60/66, 90.9% vs. placebo: n = 31/34, 91.2%). No new safety signals emerged in this subgroup analysis. Conclusion: Belimumab was efficacious for the treatment of SLE and well tolerated among the South Korean subgroup of patients from the NEA study.-
dc.language.isoen-
dc.subject.MESHAntibodies, Monoclonal, Humanized-
dc.subject.MESHAsia, Eastern-
dc.subject.MESHDouble-Blind Method-
dc.subject.MESHHumans-
dc.subject.MESHImmunosuppressive Agents-
dc.subject.MESHLupus Erythematosus, Systemic-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHSeverity of Illness Index-
dc.subject.MESHTreatment Outcome-
dc.titleEfficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia-
dc.typeArticle-
dc.identifier.pmid38140854-
dc.subject.keywordbelimumab-
dc.subject.keywordefficacy-
dc.subject.keywordsafety-
dc.subject.keywordSouth Korea-
dc.subject.keywordsystemic lupus erythematosus-
dc.contributor.affiliatedAuthorSuh, CH-
dc.type.localJournal Papers-
dc.identifier.doi10.1111/1756-185X.14997-
dc.citation.titleInternational journal of rheumatic diseases-
dc.citation.volume27-
dc.citation.number1-
dc.citation.date2024-
dc.citation.startPagee14997-
dc.citation.endPagee14997-
dc.identifier.bibliographicCitationInternational journal of rheumatic diseases, 27(1). : e14997-e14997, 2024-
dc.identifier.eissn1756-185X-
dc.relation.journalidJ017561841-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Rheumatology
Files in This Item:
38140854.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse